JP2002500677A - 新規ｎｉｄｄｍ療法 - Google Patents

新規ｎｉｄｄｍ療法

Info

Publication number
JP2002500677A
JP2002500677A JP50135099A JP50135099A JP2002500677A JP 2002500677 A JP2002500677 A JP 2002500677A JP 50135099 A JP50135099 A JP 50135099A JP 50135099 A JP50135099 A JP 50135099A JP 2002500677 A JP2002500677 A JP 2002500677A
Authority
JP
Japan
Prior art keywords
repaglinide
patients
niddm
metformin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP50135099A
Other languages
English (en)
Japanese (ja)
Inventor
ヘミングセン、リスベス・トフテ
ミューラー、ピーター・ジョルツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26064473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002500677(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2002500677A publication Critical patent/JP2002500677A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
JP50135099A 1997-06-13 1998-06-12 新規ｎｉｄｄｍ療法 Withdrawn JP2002500677A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK69497 1997-06-13
US6336897P 1997-10-29 1997-10-29
US60/063,368 1997-10-29
US0694/97 1997-10-29
PCT/DK1998/000248 WO1998056378A1 (en) 1997-06-13 1998-06-12 Novel niddm regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004000542A Division JP2004155791A (ja) 1997-06-13 2004-01-05 新規ｎｉｄｄｍ療法

Publications (1)

Publication Number Publication Date
JP2002500677A true JP2002500677A (ja) 2002-01-08

Family

ID=26064473

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50135099A Withdrawn JP2002500677A (ja) 1997-06-13 1998-06-12 新規ｎｉｄｄｍ療法
JP2004000542A Withdrawn JP2004155791A (ja) 1997-06-13 2004-01-05 新規ｎｉｄｄｍ療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004000542A Withdrawn JP2004155791A (ja) 1997-06-13 2004-01-05 新規ｎｉｄｄｍ療法

Country Status (12)

Country Link
US (1) US6677358B1 (enExample)
EP (2) EP1011673B1 (enExample)
JP (2) JP2002500677A (enExample)
AT (1) ATE201139T1 (enExample)
AU (1) AU7906898A (enExample)
DE (1) DE69800806T2 (enExample)
DK (1) DK1011673T3 (enExample)
ES (1) ES2159184T3 (enExample)
GR (1) GR3036078T3 (enExample)
PT (1) PT1011673E (enExample)
WO (1) WO1998056378A1 (enExample)
ZA (1) ZA985126B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521528A (ja) * 2000-02-01 2003-07-15 ステヴィア，エイプス 食事補強剤、又は非インシュリン依存性糖尿病、高血圧及び／又は代謝症候群の治療のための薬剤の調製に使用する物質

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4175662B2 (ja) 1996-01-08 2008-11-05 インパルス ダイナミクス エヌ．ヴイ． 電気的筋肉制御装置
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
US7006871B1 (en) 1997-07-16 2006-02-28 Metacure N.V. Blood glucose level control
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US6958324B2 (en) 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
ITMI20002019A1 (it) * 1999-09-17 2002-03-15 Novartis Ag Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AU2007201729B2 (en) * 1999-12-23 2010-02-25 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
HUP0600522A2 (en) 1999-12-23 2006-11-28 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
EP1616561B1 (en) 1999-12-28 2008-06-25 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
WO2001052860A2 (en) * 2000-01-24 2001-07-26 Inotek Corporation Method and composition for modulating an immune response
CA2403442A1 (en) * 2000-03-17 2002-09-17 Ajinomoto Co., Inc. Use of nateglinide alone or in combination for the treatment or prevention of diabetic complications
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
CA2484306A1 (en) * 2002-04-26 2003-11-06 Katsumi Maezono Prophylactic and therapeutic agent of diabetes mellitus
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
US6830759B2 (en) 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
US11439815B2 (en) 2003-03-10 2022-09-13 Impulse Dynamics Nv Protein activity modification
US9931503B2 (en) 2003-03-10 2018-04-03 Impulse Dynamics Nv Protein activity modification
US11779768B2 (en) 2004-03-10 2023-10-10 Impulse Dynamics Nv Protein activity modification
EP1898991B1 (en) 2005-05-04 2016-06-29 Impulse Dynamics NV Protein activity modification
WO2007131930A1 (en) * 2006-05-13 2007-11-22 Novo Nordisk A/S Tablet formulation comprising repaglinide and metformin
WO2008037807A1 (en) * 2006-09-29 2008-04-03 Novo Nordisk A/S Pharmaceutical formulation comprising metformin and repaglinide
CN101756971B (zh) * 2008-10-09 2013-09-18 北京德众万全药物技术开发有限公司 一种盐酸二甲双胍瑞格列奈的口服固体药物组合物
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
WO2014102715A1 (en) 2012-12-24 2014-07-03 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising a biguanide and a low dose antidiabetic agent
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
WO2018034627A1 (en) 2016-08-18 2018-02-22 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Pharmaceutical composition of antidiabetic tablet

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2118040A (en) * 1982-02-15 1983-10-26 Hoechst Uk Ltd Oral anti-diabetic preparation
SG43036A1 (en) 1991-06-21 1997-10-17 Thomae Gmbh Dr K (S) (+) -2-ethoxy-4-[N-[1-(2-piperidino-phenyl)-3-methyl- 1-buthyl]aminocarbony methyl] - benzoic a cid

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521528A (ja) * 2000-02-01 2003-07-15 ステヴィア，エイプス 食事補強剤、又は非インシュリン依存性糖尿病、高血圧及び／又は代謝症候群の治療のための薬剤の調製に使用する物質
JP2012153721A (ja) * 2000-02-01 2012-08-16 Stevia Aps 食事補強剤に使用するための、又は非インシュリン依存性糖尿病、高血圧及び／又は代謝症候群の治療のための薬剤の調製のための、物質
US9636314B2 (en) 2000-02-01 2017-05-02 Stevia Limited Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or metabolic syndrome

Also Published As

Publication number Publication date
EP1097710A3 (en) 2002-05-29
EP1097710B1 (en) 2014-08-20
HK1030872A1 (en) 2001-05-25
AU7906898A (en) 1998-12-30
PT1011673E (pt) 2001-11-30
JP2004155791A (ja) 2004-06-03
DE69800806T2 (de) 2001-09-13
ATE201139T1 (de) 2001-06-15
EP1097710A2 (en) 2001-05-09
EP1011673B1 (en) 2001-05-16
ES2159184T3 (es) 2001-09-16
GR3036078T3 (en) 2001-09-28
WO1998056378A1 (en) 1998-12-17
US6677358B1 (en) 2004-01-13
EP1011673A1 (en) 2000-06-28
DK1011673T3 (da) 2001-07-09
DE69800806D1 (de) 2001-06-21
ZA985126B (en) 1998-12-14

Similar Documents

Publication Publication Date Title
US6677358B1 (en) NIDDM regimen
Culy et al. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus
KR100769786B1 (ko) 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물
JP6442284B2 (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
US20020146372A1 (en) Method for treating diabetes mellitus
EP0735863A1 (en) Accelerated release composition containing bromocriptine
WO2000053171A1 (en) Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
KR20070089259A (ko) 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물
JP2008509145A (ja) 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
US9045438B2 (en) Pharmaceutical composition containing glimepiride and metformin hydrochloride
RU2543635C2 (ru) Способ и фармацевтические композиции для лечения постпрандиальной гипергликемии диабета ii типа введением через слизистую ротовой полости
RU2576511C2 (ru) Пероральная терапия недостаточности витамина в12
US8785469B2 (en) Method of treating atherogenic dyslipidemia
US20050222262A1 (en) Novel NIDDM regimen
US20130030053A1 (en) Novel niddm regimen
Wang Focus on repaglinide: an oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas
JP2022540862A (ja) 高濃度インスリン製剤
TWI912639B (zh) 含有氮雜環化合物之藥物組合物及其用於製備藥物的用途
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
Westphal et al. Insulin Initiation in Patients not Adequately Controlled on Oral Agents
Skugor et al. A diabetic woman with worsening heart failure, hunger, and tremor
HK1030872B (en) Novel niddm regimen
HK1102424B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
ZA200305225B (en) Spaced drug delivery system.
HK1108359B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040922

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20041108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20060119

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20060202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080715

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080718

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081209